title: Municipal pleural cancer mortality in Spain.
abstract: BACKGROUND
  Pleural cancer is a recognised indicator of exposure to asbestos and mesothelioma mortality.
  
  
  OBJECTIVE
  To investigate the distribution of municipal mortality due to this tumour, using the autoregressive spatial model proposed by Besag, York, and Mollie.
  
  
  METHODS
  It was possible to compile and ascertain the posterior distribution of relative risk on the basis of a single Bayesian spatial model covering all of Spain's 8077 municipal areas. Maps were plotted depicting standardised mortality ratios, smoothed relative risk (RR) estimates, and the distribution of the posterior probability that RR >1.
  
  
  RESULTS
  There was a higher risk of death due to pleural cancer in well defined towns and areas, many of which correspond to municipalities where asbestos using industries once existed for many years, the prime example being the municipal pattern registered for Barcelona Province. The quality of mortality data, the suitability of the model used, and the usefulness of municipal atlases for environmental surveillance are discussed.
authors.affiliation: Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain. glabente@isciii.es
authors.forename: G
authors.initials: G
authors.lastname: López-Abente
authors.forename: V
authors.initials: V
authors.lastname: Hernández-Barrera
authors.forename: M
authors.initials: M
authors.lastname: Pollán
authors.forename: N
authors.initials: N
authors.lastname: Aragonés
authors.forename: B
authors.initials: B
authors.lastname: Pérez-Gómez
mesh_terms: D001194:Asbestos / Q000009:adverse effects; D001499:Bayes Theorem; D005260:Female; D006801:Humans; D008297:Male; D010997:Pleural Neoplasms / Q000209:etiology / Q000401:mortality*; D018570:Risk Assessment / Q000379:methods; D013029:Space-Time Clustering; D013030:Spain / Q000453:epidemiology; D014504:Urban Health
chemical_list: D001194:Asbestos
references.citation: Am J Ind Med. 2000 Feb;37(2):159-68
references.pmid: 10615096
references.citation: Br J Cancer. 1999 Feb;79(3-4):666-72
references.pmid: 10027347
references.citation: Br J Cancer. 2000 Jul;83(1):104-11
references.pmid: 10883677
references.citation: Eur J Cancer Prev. 2000 Jun;9(3):179-84
references.pmid: 10954257
references.citation: Biometrics. 2000 Dec;56(4):1030-9
references.pmid: 11129458
references.citation: Stat Med. 2002 Feb 15;21(3):359-70
references.pmid: 11813223
references.citation: Oncogene. 2003 Aug 11;22(33):5164-72
references.pmid: 12910253
references.citation: Eur J Public Health. 2003 Sep;13(3 Suppl):116-8
references.pmid: 14533761
references.citation: N Engl J Med. 1982 Jun 17;306(24):1446-55
references.pmid: 7043267
references.citation: Br Med J (Clin Res Ed). 1984 Jul 14;289(6437):110-1
references.pmid: 6428677
references.citation: Int J Epidemiol. 1987 Sep;16(3):411-4
references.pmid: 3667039
references.citation: Med Clin (Barc). 1993 Nov 6;101(15):565-9
references.pmid: 8255110
references.citation: Int J Epidemiol. 1993 Dec;22(6):1193-202
references.pmid: 8144305
references.citation: Occup Environ Med. 1995 Jun;52(6):362-7
references.pmid: 7627311
references.citation: Gac Sanit. 1995 May-Jun;9(48):166-73
references.pmid: 7558629
references.citation: Eur J Epidemiol. 1996 Aug;12(4):421-3
references.pmid: 8891549
references.citation: Anticancer Res. 2000 Mar-Apr;20(2A):875-7
references.pmid: 10810369